Does DENOSUMAB Cause Malignant neoplasm progression? 767 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 767 reports of Malignant neoplasm progression have been filed in association with DENOSUMAB (Bilprevda). This represents 0.5% of all adverse event reports for DENOSUMAB.
767
Reports of Malignant neoplasm progression with DENOSUMAB
0.5%
of all DENOSUMAB reports
129
Deaths
141
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DENOSUMAB?
Of the 767 reports, 129 (16.8%) resulted in death, 141 (18.4%) required hospitalization, and 19 (2.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DENOSUMAB. However, 767 reports have been filed with the FAERS database.
What Other Side Effects Does DENOSUMAB Cause?
Off label use (34,612)
Death (16,545)
Osteonecrosis of jaw (8,438)
Arthralgia (5,890)
Pain in extremity (4,541)
Back pain (4,465)
Pain (4,102)
Product storage error (3,621)
Fall (3,322)
Fatigue (3,009)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DENOSUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
DENOSUMAB vs DEOXYCHOLIC ACID
DENOSUMAB vs DEPAKINE CHRONO
DENOSUMAB vs DEPAKOTE
DENOSUMAB vs DEPO-PROVERA
DENOSUMAB vs DERMATOPHAGOIDES FARINAE